Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

Mahran Shoukier,Marina Konopleva,Courtney D. DiNardo,Farhad Ravandi,Michael Andreeff,Guillermo Garcia-Manero,Elias Jabbour,Naval Daver,Gautam Borthakur,Naveen Pemmaraju,Guillermo Montalban Bravo,Christopher B. Benton,Nicholas J. Short,Kapil N. Bhalla,Jorge E. Cortes,Hagop M. Kantarjian,Tapan M. Kadia

Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

2019

Mahran Shoukier
Marina Konopleva
Courtney D. DiNardo
Farhad Ravandi
Michael Andreeff
Guillermo Garcia-Manero
Elias Jabbour
Naval Daver
Gautam Borthakur
Naveen Pemmaraju
Guillermo Montalban Bravo
Christopher B. Benton
Nicholas J. Short
Kapil N. Bhalla
Jorge E. Cortes
Hagop M. Kantarjian
Tapan M. Kadia

7034Background: Mutations in TP53 are associated with low response rates to standard therapy and poor outcomes in patients (pts) with acute myeloid leukemia (AML). Combination therapy with the BCL2...

Keywords:

Pathology
Combination therapy
Myeloid leukemia
Internal medicine
Oncology
Medicine
Venetoclax
standard therapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations